General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Boehringer Ingelheim(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Lilly US(MODEST), Pfizer Inc(NONE), Bayer(SIGNIFICANT), New Amsterrdam(SIGNIFICANT), Neurotronic(SIGNIFICANT), Kailera(MODEST), Metsera(MODEST), Alveus(MODEST) RESEARCH/RESEARCH GRANTS: Boehringer Ingelheim(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), AstraZeneca(SIGNIFICANT), Esperion(MODEST), Lilly USA(SIGNIFICANT)

View Full Disclosure